医学
多西紫杉醇
不利影响
不良事件报告系统
紫杉醇
肿瘤科
内科学
置信区间
安全概况
生存分析
药品
作者
Naohito Ide,Yoshifumi Kudo,Ken-ichi Sako,Tomoji Maeda
标识
DOI:10.1080/1120009x.2026.2663679
摘要
Taxanes such as paclitaxel and docetaxel are widely used in malignancies but may cause rare ophthalmic toxicities, including macular oedema. This study clarified occurrence patterns and time to onset by analysing the FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER). In total, 4880 macular oedema cases were reported in FAERS and 523 in JADER; 306 and 97 cases were attributed to paclitaxel, and 54 and 13 to docetaxel, respectively. Disproportionality analysis showed positive reporting signals. Median onset times were 115 d in FAERS and 145 d in JADER for paclitaxel and 104 d in FAERS for docetaxel. Weibull shape parameters indicated a random pattern. Outcomes were mostly favourable for paclitaxel, whereas docetaxel cases showed more non-recovery or sequelae in JADER. Taxane-induced macular oedema is a clinically relevant adverse event requiring continuous ophthalmologic monitoring, and potential regional differences and patient-level risk factors warrant further study.
科研通智能强力驱动
Strongly Powered by AbleSci AI